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RAIMUND HIRSCHBERG and JOEL D. KOPPLE
Division of Nephrology and Hypertension, Harbor—UCLA Medical Center, Torrance, California, USA
Role of growth hormone in the amino acid—induced acute rise in renal
function in man. To examine whether plasma growth hormone is
necessary for the amino acid—induced rise in effective renal plasma flow
(ERPF, PAH clearance) and GFR (inulin clearance), arginine HCI, 500
mg/kg, was infused for 30 minutes into eight normal and six growth
hormone—deficient individuals. During infusion, ERPF increased in the
normal and growth hormone—deficient subjects by 28.9 11.4 sD-% (P
<0.01) and 46.5 14.4% (P < 0.001). GFR rose by 23.7 5.9% (P <
0.05) and 42.7 29.1% (P < 0.001) in the two groups. Plasma growth
hormone rose only in the normal subjects, while glucagon increased in
both groups. Infusion of arginine HCI, 200 mg/kg, into normals in-
creased ERPF and GFR without increasing plasma osmolality. Lower
arginine doses essentially did not affect ERPF, GFR, growth hormone,
or glucagon. Infusion of D-glucose into normals raised plasma osmolal-
ity as high as with arginine HCI, 500 mg/kg, but increased ERPF only
slightly and not GFR; D-glucose infusion caused a delayed rise in
growth hormone that was unassociated with an increase in ERPF or
GFR. An infusion of ammonium chloride with sodium chloride, which
provided an amount of chloride similar to the 500 mg/kg arginine HCI
dose, did not change ERPF and GFR; this suggests that the chloride
load did not cause the altered renal hemodynamics stimulated by
arginine HCI. These findings indicate that neither normal plasma
growth hormone levels nor a rise in growth hormone mediates the
arginine—induced acute increase in ERPF or GFR. This effect is also not
due to the osmolar load but could be caused by the rise in plasma
glucagon.
Humans and animals undergo a transient but reproducible
increase in renal plasma flow (RPF) and glomerular filtration
rate (GFR) in response to an amino acid or protein load [1—4].
Although several studies have examined the mechanisms un-
derlying this response, the factors controlling these processes
are still not well defined. Growth hormone has been implicated
as a possible cause of the amino acid or protein induced rise in
RPF and GFR. The evidence stated briefly is as follows: (a)
plasma growth hormone rises rapidly but transiently in re-
sponse to a protein or amino acid load [51; (b) injections of
growth hormone for several days increases RPF and GFR in
humans [6, 7]; (c) acromegaly, a disease with chronically—elev-
ated plasma growth hormone concentrations, is also associated
with high RPF and GFR [81; (d) a protein meal increases GFR
in normal individuals but not in growth hormone—deficient
patients [9].
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The present study was undertaken to examine in greater
detail whether the presence of normal plasma growth hormone
levels or a rise in plasma growth hormone is necessary for the
amino acid—induced rise in RPF and GFR. The question was
addressed by infusing intravenously arginine hydrochloride, a
potent secretagogue for growth hormone, into normal individ-
uals and patients with growth hormone deficiency.
Methods
Studies were carried out in six patients with growth hormone
deficiency and 27 normal individuals who were subjected to one
or more of the following infusion protocols: Three men and
three women with growth hormone deficiency, aged 33 7 (SD)
years, and four male and four female normal volunteers, aged30 5 years, were infused for 30 minutes with arginine HCI,
500 mg/kg body weight or 30 g, whichever was less. Their
weights were 67.7 1.4 and 62.9 5.0 kg, respectively. Three
men and one woman, 35 6 years old, and all normal, received
200 mg/kg of arginine. Three normal men, 26 4 years old,
received 50 mg/kg arginine HC1; two men and one woman,
normal, and 29 3 years old, were given 10 mg/kg of arginine
HC1 and three male and two female normal volunteers, 32 5
years old, received 1000 mg/kg of D-glucose monohydrate. This
latter compound was infused as 5 mi/kg of 20% dextrose (900
mg/kg of anhydrous glucose) up to a maximum of 300 ml of the
dextrose solution. Finally, five normal men, 33 4 years old,
were infused with 70 mmol of ammonium chloride and 70 mmol
of sodium chloride in 300 ml water over 30 minutes.
The subjects showed no evidence of disease except for the
endocrine disorders in the growth hormone—deficient patients.
The causes of growth hormone deficiency were hereditary
isolated growth hormone deficiency (one patient), hereditary
panhypopituitarism (one patient), secondary panhypopituitar-
ism due to Sheehan's syndrome (two patients), and hypophy-
sectomy for nonmalignant tumors (two patients). The growth
hormone—deficient patients received replacement therapy with
thyroid (five subjects), testosterone (three patients),and pred-
nisone (three subjects). Only two of the six patients had
received growth hormone injections, but not for at least seven
years before the study.
The subjects were fasted from midnight before the experi-
ment until the study was completed. The only exception was
water. The individuals drank 1000 ml of deionized water be-
tween 7:20 and 8:00 a.m. and 300 ml of deionized water every
hour thereafter at exactly ten minutes before the hour. At 8:00
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a.m. inulin (American Critical Care, McGaw Park, Illinois), 60
mg/kg of body weight, and para-aminohippuric acid (PAH,
Merck, Sharp and Dohme, West Point, Pennsylvania, USA), 8
mg/kg body weight, were injected intravenously. This was
followed by a continuous infusion of inulin, 0.5 mg/kg/mm, and
PAH, 0.25 mg/kg/mm, in normal saline, at 31 mI/hr which lasted
until 3:30 p.m. After one hour for equilibration, subjects began
14 clearance periods of 30 minutes each. Blood was drawn at
the beginning and end of each clearance period to measure
plasma inulin, PAH, sodium, osmolality and arginine. Between
11:30 a.m. and 12:00 noon, individuals received an infusion of
10% arginine HCI (R-Gene, Cutter Lab, Berkeley, California,
USA) or 20% dextrose in water as discussed above. The 10%
arginine HCI solution used in this study contained no potassium
or sodium, and the osmolality of the infusate was measured in
our laboratory to be 801 mOsm/kg. Immediately before and
every 15 to 30 minutes after the onset of the arginine or dextrose
infusion, blood was taken for plasma growth hormone and
glucagon levels.
The ammonium chloride and sodium chloride solution was
also infused from 11:30 a.m. to 12:00 noon. However, the
protocol differed with the latter infusion in that only seven, 30
minute PAH and inulin clearances were performed; three
before, one during and three after the infusion. Also, growth
hormone, glucagon, sodium and arginine were not measured.
Effective renal plasma flow (ERPF) and glomerular filtration
rate (GFR) were measured as the PAH and inulin clearances,
respectively. Plasma PAH and inulin at the beginning and end
of each clearance period were averaged for calculation of the
clearance values. PAH and inulin were measured in plasma and
urine as previously described [10, 11]. Two specimens were
obtained at each blood drawing for measurement of PAH and
inulin concentrations; each specimen was analyzed in duplicate
or triplicate. A pooled control sample of plasma was measured
with each batch of inulin and PAR determinations. The coeffi-
cients of variation for the analyses of the pooled controls were
2.9% for PAH and 4.3% for inulin. Sodium was measured in
plasma and urine with a flame photometer (Model 143, Instru-
mentation Laboratory, Boston, Massachusetts, USA). Plasma
osmolality was determined by freezing point depression
(Microosmette Model 5004, Precision Systems, Sudbury, Mas-
sachusetts, USA).
Plasma human growth hormone was measured by radioim-
munoassay in the Harbor-UCLA Clinical Research Center
Laboratory using rabbit anti-human growth hormone anti-
serum. Plasma glucagon was measured by radioimmunoassay in
the laboratory of Dr. Seymur Levin. Plasma arginine was
measured with an automated amino acid analyzer, Model 121
MB (Beckman Instruments, Fullerton, California, USA). In
subjects who received the glucose infusion, plasma glucose was
measured with a glucose analyzer (Beckman Instruments). Data
were analyzed by analysis of variance (when multiple baseline
measurements were obtained) or by Student's or unpaired
(-test. Results are presented as means and standard deviations.
Results
The plasma arginine concentrations during and after the
arginine infusions are shown in Figure 1. In the normal subjects,
there was a direct relation between the quantity of arginine
infused, expressed per kg body weight, and the maximum rise
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Fig. 1. Mean plasma arginine concentrations before, during and after
arginine HCI infusion in growth hormone deficient (GH DEF) patients
and normal subjects infused with varying doses of arginine HG!. The
shaded bar indicates the time of infusion. The asterisks indicate a
significant difference (P < 0.05) between the growth hormone deficient
and normal subjects infused with 500 mg/kg of arginine HCI. Symbols
are: (0) GH DEF, 500 mg/kg; (•) normal, 500 mg/kg; (X) normal, 200
mg/kg; (A) normal, 50 mg/kg; (•) normal, 10 mg/kg.
in arginine level (r = 0.802, P < 0.05). The maximum increase
in plasma arginine in the growth hormone—deficient patients
was not significantly greater than in the normal individuals who
received 500 mg arginine HC1/kg. However, the plasma arginine
concentrations were greater in the growth hormone deficient
patients as compared to the latter individuals at 60 minutes, and
2.5 to 4.5 hours after the arginine infusion (Fig. 1). The actual
intake of arginine HCI in the growth hormone deficient and
normal subjects was 439 95 and 450 66 mg/kg, respectively.
The ERPF, GFR, and plasma growth hormone and glucagon
levels are shown in Figure 2 and Table 1. For ERPF, GFR, and
the fractional excretion of sodium, the baseline period for each
patient is defined as the mean of the four clearance periods
immediately prior to the infusion of arginine or glucose. During
the baseline period, these parameters did not change.
In the normal and growth hormone—deficient subjects receiv-
ing arginine HCI, 500 mg/kg, there was a significant increase in
ERPF of28.9 11.4% (P < 0.01) and 46.5 14.4% (P <0.001),
respectively. Although the maximal ERPF levels did not differ
ARG HCI
.5)
0
E
:1
a)
C
C
0)
Ca
a)
E
U)
Ca
a-
14000-
12000-
10000-
8000-
6000-
4000-
2000- *
0-
* * *
0 3 4
384 Hirschberg and Kopple
-
. CCC')
(D
30
Ec— 20I ':
800
600
- 400
20:
—2 —1 0 i 2 3 4 5
Time, hours
Fig. 2. ERPF, GFR, plasma growth hormone and plasma glucagon in
response to an infusion of arginine HC1 in growth hormone deficient (0,
500 mg/kg) and normal subjects (•, 500 mg/kg). The shaded bar
indicates the period of the arginine HCI infusion. Significantly greater
than the subjects' baseline or pre-infusion values: * < 0.05, **P <
0.01, < 0.001.
between the two groups, the magnitude of the rise, expressed in
absolute values or as a percent change was significantly greater
in the growth hormone—deficient patients (P < 0.05). In both,
the normal and growth hormone—deficient individuals, there
was a significant rise in GFR during the arginine infusion of 23.7
5.9% (P < 0.05) and 42.7 29.1% (P < 0.001), respectively.
This rise in GFR whether expressed in absolute values or as a
percent increase, did not differ significantly between the two
groups. In the individuals receiving 200 mg/kg of arginine HC1,
the rise in ERPF and GFR was not different from the normal
subjects infused with arginine HCI, 500 mg/kg (Table 1). The
rise in ERPF and GFR in these three groups was rapid, reaching
maximum levels during the arginine infusion and falling back to
baseline during the 30 or 60 minute period that followed the
infusion. There was no significant rise in ERPF or GFR in the
normal subjects who received 50 or 10 mg/kg of arginine HCI.
During the arginine infusion, plasma growth hormone did not
rise in the growth hormone—deficient patients. In the normal
subjects receiving 500 or 200 mg/kg of arginine HCI plasma
growth hormone was not increased after 15 minutes of the
infusion, but was significantly elevated at the end of the infusion
and attained maximum levels at 45 and 60 minutes after the
onset of the arginine administration (Fig. 2 and Table 1).
Following the infusion, plasma growth hormone levels de-
creased gradually to preinfusion levels. Plasma growth hor-
mone rose slightly but significantly only at 45 minutes after the
onset of the infusion in the subjects receiving 50 mg/kg of
arginine HCI, and did not rise in the individuals receiving 10
mg/kg of this compound (Table 1).
Plasma glucagon concentrations increased within 15 minutes
of infusion in both the growth hormone—deficient patients and in
the normal subjects who received either 500 or 200 mg/kg of
arginine HCI and fell gradually back to baseline after the
infusion. Plasma glucagon did not increase significantly in the
subjects who received 50 mg/kg or 10 mg/kg of arginine HCI
(Table 1).
The maximum plasma osmolality was observed at the end of
the infusion (Table 1). In the growth hormone deficient and
normal individuals receiving arginine HCI, 500 mg/kg, the rise
in plasma osmolality was 9 3 and 11 5 mOsm!kg, respec-
tively. After the infusion, osmolality fell progressively to base-
line. There was no significant increase in plasma osmolality in
the individuals receiving lesser quantities of arginine.
Since it is possible that a rise in plasma osmolality and blood
volume induced by the arginine infusion caused the increase in
ERPF and GFR, a control group of five normal subjects was
infused for 30 minutes with 1000 mg/kg of D-glucose monohy-
drate or 60 g, whichever was less. This infusion increased
plasma osmolality to 11 4 mOsm/kg, which was similar to the
rise in the normal and growth hormone deficient subjects who
received 500 mg/kg of arginine HCI (Table 1). However, the
maximum increase in ERPF and GFR after D-glucose infusion
was only 11.2 7.2% (P < 0.05) and 8,7 8.4% (P NS),
respectively, (Table 1, Fig. 3). This increase in ERPF and GFR
was significantly less than in the normal individuals infused with
either 500 or 200 mg/kg of arginine HC1 (at each dose of arginine
infused, P <0.05 for ERPF and P < 0.05 for GFR) and in the
growth hormone-deficient patients (P < 0.05 for each compar-
ison).
During the glucose infusion, when the ERPF rose and the
GFR tended to increase there was no associated elevation in
plasma growth hormone or glucagon (Fig. 3). However, plasma
growth hormone increased significantly between three and four
hours after the onset of the infusion to a maximum value of 11.2
5.8 ng/ml. ERPF and GFR were not elevated above baseline
at this time.
The infusion of 70 mmol ammonium chloride with 70 mmol
sodium chloride in 300 ml water was carried out to assess
whether the chloride load without arginine might increase
ERPF and GFR. There was no change in either ERPF or GFR
with this infusion (Table 1). The plasma osmolality rose by 8
2 mOsm/kg (Table 1), which was of about the same magnitude
and not significantly different from the increase in the normal
and growth hormone—deficient patients given 500 mg/kg of
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Table 1. Response of renal function and plasma hormones and osmolality to arginme or glucose infusion
Effective renal plasma flow Glomerular filtration rate
(mi/mini). 73m2 mi/mini). 73m2
No. of Minutes
subjects Dose Base
Group studied Infusate mg/kg line 0—30 30—60 90l20a
MinutesBase
line 0—30 30—60 90—120
GH Deficient 6 Arginine HC! 500 436" 63l' 492 464 81 lll' 88 84
±86 ±95 ±115 ±118 ±17 ±11 ±18 ±22
Normal 8 Arginine HCI 500 486 623C 435 498 100 124" 96 105
±70 ±77 ±96 ±107 ±10 ±15 ±16 ±24
Normal 4 Arginine HCI 200 475 611" 460 468 104 125" 90 97
±73 ±188 ±41 ±91 ±12 ±14 ±9 ±17
Normal 3 Arginine HCI 50 528 512 483 507 102 102 96 100
±102 ±96 ±101 ±96 ±5 ±6 ±15 ±18
Normal 3 Arginine HCI 10 513 499 475 504 102 99 95 96
±91 ±76 ±98 ±99 ±6 ±7 ±2 ±11
Normal 5 Glucose 1000 523 584d 502 507 99 108 95 100
monohydrate ±63 ±95 ±94 ±129 ±13 ±16 ±17 ±18
Normal 5 NH4CI + NaCI see 494 478 472 488 105 103 104 106
belowa ±38 ±83 ±51 ±64 ±5 ±9 ±7 ±4
a Indicates duration of time in minutes after the onset of the respective 30 minute infusion.
b Values are expressed as mean ± SD.
C Each individual received 70 mmol of NH4CI with 70 mmol of NaCl in 300 ml water.
Significantly different from baseline values, " P < 0.05, P < 0.01, P < 0.001.
Table 1. (Continued)
Plasma growth hormone mg/,'ni Plasma glucagon pg/mi Plasma osmolality mosm/kg
Minutes MinutesBase Base
line 30 45 60 120 line 30 45 60 120
MinutesBase
line 30 45 60 240
0.5 0.7 0.8 0.8 0.7 177 663 485C 388 203 274 283" 281 278 275
±0.1 ±0.3 ±0.3 ±0.3 ±0.3 ±83 ±202 ±236 ±138 ±82 ±7 ±10 ±10 ±10 ±6
0.8 11.3" 24.0e 23.5e 82d 181 678 572C 408" 224 278 289 283 283 282
±0.8 ±11.0 ±19.1 ±16.9 ±10.5 ±63 ±209 ±193 ±205 ±69 ±4 ±5 ±7 ±6 ±7
1.1 65d l3.2 l3.8' 2.6 145 3S9 190C 159 118 279 282 280 280 274
±1.2 ±5.7 ±11.7 ±16.6 ±2.3 ±16 ±76 ±49 ±39 ±56 ±6 ±6 ±6 ±4 ±6
0.5 4.3 4.4" 2.1 0.7 158 193 119 129 146 273 275 274 273 275
±0.0 ±6.5 ±6.8 ±2.6 ±0.2 ±7 ±60 ±10 ±20 ±28 ±1 ±1 ±2 ±2 ±3
7.9 4.3 2.3 1.4 1.0 143 117 119 113 113 280 279 281 282 279
±6.7 ±4.2 ±2.2 ±1.1 ±0.3 ±53 ±64 ±44 ±66 ±44 ±2 ±2 ±3 ±2 ±2
1.6 2.6 2.5 1.2 1.3 165 122 129 136 200 285 296C 292 287 285
±1.3 ±3.5 ±3.4 ±0.4 ±0.6 ±80 ±92 ±91 ±111 ±129 ±3 ±4 ±4 ±6 ±4
281 289C 284 280 281
±3 ±4 ±4 ±1 ±3
arginine HCI. Moreover, the rise in plasma osmolality with the
ammonium and sodium chloride infusion was greater than with
the 200 mg/kg of arginine HCI infusion (P < 0.05), where there
was no significant change in plasma osmolality (+ 3 ± 4
mOsm/kg).
The fractional excretion of sodium rose in the growth
hormone—deficient patients and the normal subjects infused
with 500 or 200 mg/kg of arginine HCI (Fig. 4). The rise was
most dramatic in the growth hormone—deficient patients, where
the fractional sodium excretion increased from 1.78 ± 0.89%
during baseline to a maximum value of 5.30 ± 2.72% which
occurred one hour after the onset of the arginine infusion. The
rise in the normal subjects given 500 or 200 mg/kg of arginine
HCI was more gradual, and the maximum increase, which was
less marked, occurred four or four and one—half hours after the
end of the infusion (Fig. 4).
Discussion
This study was carried because of previous reports that in
man and several animals an oral protein load or intravenous
infusion of amino acids causes a rapid but transient increase in
RPF and GFR [2—4]. Peptide hormones have been suggested as
a cause of this response because somatostatin, which blocks the
secretion of these hormones, also prevents the amino acid
induced rise in RPF and GFR [4]. Both growth hormone and
glucagon have been implicated [4, 7, 9].
We tested the hypothesis that either the presence of normal
plasma growth hormone concentrations or a rise in plasma
growth hormone—levels is necessary for the amino acid induced
rise in RPF and GFR. L-arginine HCI, a potent secretogogue of
growth hormone [12], was infused into both normal and growth
hormone—deficient subjects. Both groups exhibited a substan-
tial and transient increase in RPF and GFR, which was similar
in magnitude to the rise after an oral protein load or mixed
amino acid infusion in humans [4, 9]. The finding that plasma
growth hormone was very low and did not increase during the
arginine infusion and increased mainly after the infusion only in
the normal subjects indicates that growth hormone did not
mediate the arginine induced rise in RPF and GFR.
Other findings in this study also suggest that growth hormone
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Fig. 3. ERPF, GFR, plasma growth hormone, glucagon and glucose
levels in normal subjects infused with D-glucose. Significantly greater
than baseline or pre-infusion values: * < 0.05, < 0.01, **P <
0.001.
does not play a role in the amino acid—induced acute rise in RPF
and GFR. First, in the normal subjects, the maximum rise in
growth hormone occurred after the rise in RPF and GFR.
However, this discrepancy could be explained by an all or none
response whereby when a certain plasma hormone level is
attained, a maximal response is elicited and an additional
increase in hormone stimulates no further response. Second, in
the normal individuals who were infused with D-glucose, there
was a small increase in RPF during the infusion even though
plasma growth hormone—levels did not change. Third, in these
same individuals, there was a delayed, approximately ninefold
increase in plasma growth hormone—levels. This rise was ap-
proximately of the same magnitude as that observed in our
normal subjects infused with 200 mg/kg of arginine HC1. How
ever, in the individuals given D-glucose, the rise in plasma
growth hormone was associated with, if anything, a tendency
for RPF and GFR to fall.
Since the plasma arginine concentrations rose greatly with
Fig. 4. Fractional excretion of sodium in response to an infusion of
arginine HCI or glucose in growth hormone deficient and normal
subjects. Significantly greater than baseline values: * < 0.05, <
0.01, < 0.001.
the 500 mg/kg dose, to 8055 2191 and 13963 7404 tmol/liter
in the normal and growth hormone—deficient subjects, we
studied the response to lower doses of arginine HC1 in the
normal individuals. The purpose of this study was to evaluate
the effect on growth hormone and renal function of an amino
acid load that was more physiological. When 200 mg/kg of
arginine HC1 was administered, the maximum rise in plasma
arginine values, to 2342 1527 .tmoL1liter, was similar to the
total increase in plasma amino acids that occurs after a protein
meal. Although plasma growth hormone and glucagon rose
somewhat less with this infusion, the increment in RPF and
GFR was similar to that of the normal individuals given 500
mg/kg of arginine HCI. Infusions of lower doses of arginine
HC1, 50 and 10 mg/kg, were carried out in normal subjects to
assess whether RPF and GFR would increase in the absence of
a rise in growth hormone. We were unable to demonstrate such
an effect, and so these studies were not continued.
The lower doses of arginine were also infused to investigate
the possibility that the 500 mg/kg dose of arginine HC1 increased
RPF and GFR by an osmotic effect that increased plasma
volume. The finding that, in the normal individuals given 200
mg/kg of arginine HCI, there was an increase in RPF and GFR
but not in plasma osmolality suggests that an increase in plasma
volume was not a major cause of the increase in renal function.
This same issue was examined by infusing the D-glucose
solution in a volume of water equal to the 500 mg/kg arginine
HC1 infusion. In this study, the osmolality increased to the
same degree as in the normal and growth hormone-deficient
subjects who received 500 mg/kg of arginine HC1. The ERPF,
however, rose much less, and the GFR did not rise significantly.
A small rise in ERPF and GFR with D-glucose infusion has
been observed previously in humans and rats [3, 131. These
observations that osmotic and volume loads do not have a
major effect on RPF and GFR has been reported by Meyer and
Brenner [31.
The ammonium chloride and sodium chloride solution pro-
vided the same osmolar and chloride load as the 500 mg/kg
ARG HCI
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arginine HCI infusion. The finding that there was no change in
ERPF and GFR with the former infusion indicates that neither,
the osmolar nor the chloride load can account for the increase
in renal hemodynamics with the arginine infusion.
Several investigators have implicated tubuloglomerular feed-
back as a mechanism contributing to the amino acid or protein
induced increase in GFR [14—17]. However, during infusion of
500 mg/kg or 200 mg/kg of arginine HCI, the fractional excretion
of sodium increased in the growth hormone deficient and
normal subjects. These findings, although not conclusive,
would suggest that the arginine HCI infusion, if it had any effect
on tubuloglomerular feedback, would stimulate it to reduce the
GFR. It is therefore unlikely that this mechanism could account
for the arginine HCL-induced rise in RPF and GFR,
The results of the present study suggest that growth hormone
does not mediate the acute amino acid—induced rise in RPF and
GFR.
The finding of Kleinman and Glassock that after a large
protein meal, GFR increased in all normal individuals but not in
growth hormone—deficient subjects is puzzling [91. However,
plasma growth hormone rose in only one of their four normal
subjects. This also indicates that an increase in plasma growth
hormone is not necessary for the acute rise in GFR after the
protein load. The authors conclude that a pituitary—hypo-
thalamic disorder, other than the growth hormone deficiency,
may be responsible for the failure of GFR to increase in the
growth hormone—deficient patients [91.
Parving and associates observed no increase in RPF or GFR
in normal individuals who were infused with growth hormone
for two hours [18]. The finding that growth hormone injections
for several days increased RPF and GFR suggests that persist-
ent or recurrent elevations of this hormone could increase RPF
and GFR [6, 7]. Serum somatomedin levels may not increase
until many hours after plasma growth hormone rises [19].
Hence, the finding that a rise in plasma growth hormone for
several days causes a delayed increase in RPF and GFR may
indicate that these latter efffects are mediated by somato-
medins.
In the present study, the rise and peak values of plasma
glucagon after the infusion of 500 mg/kg or 200 mg/kg of arginine
HC1 occurred at the same time that RPF and GFR increased in
the normal and growth hormone—deficient subjects. These
findings are consistent with the observations by other workers
that an infusion of glucagon in dogs or humans can acutely
increase RPF and GFR [20—231.
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